Cohort1: dose escalation_dose level 1
|
Administration route |
intravenous infusion |
Dosage |
3E7 cells |
Donor type |
Autologous |
Pts |
3 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
2/3(All-cause Mortality) |
|
Cohort2: dose escalation_dose level 2
|
Administration route |
intravenous infusion |
Dosage |
1E8 cells |
Donor type |
Autologous |
Pts |
4 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
4/4(All-cause Mortality) |
|
Cohort3: dose escalation_dose level 3
|
Administration route |
intravenous infusion |
Dosage |
3E8 cells |
Donor type |
Autologous |
Pts |
3 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
3/3(All-cause Mortality); 1/3(General disorders; Respiratory, thoracic and mediastinal disorders) |
|
Cohort4: dose escalation_dose level 4
|
Administration route |
intravenous infusion |
Dosage |
1E9 cells |
Donor type |
Autologous |
Pts |
4 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
3/4(All-cause Mortality) |
|
Cohort5: dose expansion_dose level 1
|
Administration route |
intravenous infusion |
Dosage |
3E7 cells |
Donor type |
Autologous |
Pts |
3 |
Age |
Adult, Older_Adult |
Lymph depletion |
Yes |
Adverse reactions |
3/3(All-cause Mortality) |
|